You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Screening for Hepatocellular Carcinoma in Patients with Cirrhosis

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis who underwent imaging with either ultrasound, contrast enhanced CT or MRI for hepatocellular carcinoma (HCC) at least once within the 12 month reporting period.

Date Reviewed: November 19, 2017

Measure Info

MIPS 401CMS 401CQMC Core Measure
Measure Type: 
Measure Steward: 
American Gastroenterological Association
Clinical Topic Area: 
Hepatitis C

Care Setting: 
Data Source: 

ACP does not support QPP measure 401: "Hepatitis C: Screening for Hepatocellular Carcinoma" because the screening benefits do not outweigh the substantial risks of harms related to radiation exposure and treatment of incidental findings. Furthermore, developers cite weak evidence to form the basis of the measure. A recent evidence review demonstrates insufficient evidence for screening for hepatocellular carcinoma among patients with cirrhosis.